Erratum: Botulinum toxin type a therapy during pregnancy. Mov Disord 2004;19(11):1384-1385
نویسندگان
چکیده
منابع مشابه
Botulinum toxin type A in pregnancy.
QUESTION My patient received 62 units of botulinum toxin type A (BTX-A) for facial lines. Two weeks later, she found out that she was pregnant. Will this cause any harm to her fetus? ANSWER Botulinum toxin is not expected to be present in systemic circulation following proper intramuscular or intradermal injection. Moreover, BTX-A, which has a high molecular weight, does not appear to cross t...
متن کاملBotulinum toxin A during pregnancy: a survey of treating physicians.
Botulinum toxin A (btxA) is widely used for cosmetic purposes, headaches, dystonia, spasticity, pain and other on and off label uses. Despite the widespread use of btxA in women of childbearing potential, there are few data on the effects of this drug on pregnant women and the fetus. The goal of this study was to survey physicians who use btxA, to determine their experience with pregnant women....
متن کاملStabilization of botulinum toxin type A during lyophilization.
Botulinum toxin for medical use is diluted to very low concentrations (nanograms per milliliter); when it is preserved by lyophilization, considerable loss of activity can occur. In the present study, conditions that gave > 90% recovery of the toxicity after lyophilization of solutions containing 20 to 1,000 mouse 50% lethal doses per ml were found. Toxicity was recovered upon drying 0.1 ml of ...
متن کاملBotulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A.
BACKGROUND Botulinum toxin type B (BTX-B; Myobloc) has recently been introduced for the treatment of dynamic rhytides. This serotype is structurally similar to botulinum toxin type A (BTX-A; Botox) and appears to produce equivalent muscular paralysis. Because of the fact that some patients may become resistant to the effects of BTX-A with its continued use or may require large doses of type A t...
متن کاملbotulinum toxin type a therapy in migraine: preclinical and clinical trials
conclusions the evidence that btx-a decreases ntg-induced cgrp-li and sp-li levels in trigeminovascular system suggests that btx-a attenuates migraine by suppression of neuropeptide release. btx-a injections for migraine at acupoint-sites and fixed-sites are effective. acupoint-sites btx-a administration shows more efficacy for migraine than fixed-sites application. results local btx-a injectio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Movement Disorders
سال: 2004
ISSN: 0885-3185
DOI: 10.1002/mds.20338